NEA Management Company
Latest statistics and disclosures from NEA Management Company's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACLX, CRSP, RYTM, SVRA, COUR, and represent 49.48% of NEA Management Company's stock portfolio.
- Added to shares of these 4 stocks: ORIC (+$21M), Regulus Therapeutics (+$13M), Affimed N V Ordinary, XERS.
- Started 3 new stock positions in ORIC, XERS, Affimed N V Ordinary.
- Reduced shares in these 9 stocks: GERN (-$33M), SGMT (-$10M), MYND (-$8.6M), GLYC, Affimed Therapeutics B V, ACRV, ADXN, SYBX, UP.
- Sold out of its positions in ACRV, ADXN, Affimed Therapeutics B V.
- NEA Management Company was a net seller of stock by $-22M.
- NEA Management Company has $1.6B in assets under management (AUM), dropping by 7.37%.
- Central Index Key (CIK): 0001512848
Tip: Access up to 7 years of quarterly data
Positions held by NEA Management Company consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for NEA Management Company
NEA Management Company holds 44 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Arcellx Common Stock (ACLX) | 16.2 | $261M | 3.7M | 69.55 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 11.2 | $180M | 1.6M | 113.62 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 7.8 | $126M | 2.9M | 43.33 |
|
|
| Savara (SVRA) | 7.6 | $122M | 25M | 4.98 |
|
|
| Coursera (COUR) | 6.7 | $108M | 13M | 8.41 |
|
|
| Korro Bio (KRRO) | 6.0 | $97M | 1.1M | 90.00 |
|
|
| Verona Pharma Sponsered Ads (VRNA) | 5.6 | $90M | 5.1M | 17.59 |
|
|
| Monte Rosa Therapeutics (GLUE) | 3.4 | $54M | 7.7M | 7.05 |
|
|
| Nextnav Common Stock (NN) | 3.3 | $54M | 8.2M | 6.58 |
|
|
| CVRX (CVRX) | 2.7 | $43M | 2.4M | 18.21 |
|
|
| Geron Corporation (GERN) | 2.6 | $42M | -43% | 13M | 3.30 |
|
| Trevi Therapeutics (TRVI) | 2.4 | $39M | 11M | 3.45 |
|
|
| Nkarta (NKTX) | 2.4 | $39M | 3.6M | 10.81 |
|
|
| Celcuity (CELC) | 1.7 | $27M | 1.3M | 21.60 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 1.7 | $27M | 17M | 1.58 |
|
|
| Black Diamond Therapeutics (BDTX) | 1.4 | $23M | 4.4M | 5.07 |
|
|
| X4 Pharmaceuticals (XFOR) | 1.3 | $21M | 15M | 1.39 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.3 | $21M | 2.0M | 10.62 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.3 | $21M | NEW | 1.5M | 13.75 |
|
| ZeroFox Holdings (ZFOX) | 1.3 | $20M | 18M | 1.12 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 1.2 | $20M | 4.0M | 5.01 |
|
|
| Gossamer Bio (GOSS) | 1.2 | $19M | 16M | 1.18 |
|
|
| Inozyme Pharma (INZY) | 1.2 | $19M | 2.4M | 7.66 |
|
|
| Regulus Therapeutics | 1.2 | $19M | +232% | 6.5M | 2.88 |
|
| Neuehealth Com New (NEUE) | 1.1 | $18M | 2.7M | 6.50 |
|
|
| Desktop Metal Com Cl A (DM) | 0.8 | $13M | 14M | 0.88 |
|
|
| Glycomimetics (GLYC) | 0.7 | $12M | -19% | 3.8M | 3.00 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.7 | $11M | -48% | 2.0M | 5.42 |
|
| Tuya Sponsered Ads (TUYA) | 0.5 | $8.6M | 4.9M | 1.75 |
|
|
| Champions Oncology Com New (CSBR) | 0.5 | $8.4M | 1.7M | 4.90 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.5 | $7.9M | 4.8M | 1.66 |
|
|
| Allakos (ALLK) | 0.5 | $7.7M | 6.1M | 1.26 |
|
|
| Buzzfeed Class A Com (BZFD) | 0.4 | $7.2M | 15M | 0.47 |
|
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.4 | $5.7M | 2.4M | 2.40 |
|
|
| Inventiva Sa Ads (IVA) | 0.3 | $5.3M | 1.5M | 3.62 |
|
|
| Synlogic Com New (SYBX) | 0.3 | $5.2M | 2.9M | 1.79 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.3 | $4.6M | 1.1M | 4.30 |
|
|
| Affimed Nv Ordinary Shs New | 0.1 | $2.3M | NEW | 443k | 5.30 |
|
| Senti Biosciences Ord (SNTI) | 0.1 | $1.7M | 4.4M | 0.38 |
|
|
| Mynd Ai Spon Ads (MYND) | 0.1 | $1.6M | -84% | 3.6M | 0.43 |
|
| Xeris Pharmaceuticals (XERS) | 0.1 | $926k | NEW | 419k | 2.21 |
|
| Ikena Oncology (IKNA) | 0.1 | $810k | 570k | 1.42 |
|
|
| Wheels Up Experience Com Cl A (UP) | 0.0 | $305k | 106k | 2.87 |
|
|
| Surf Air Mobility (SRFM) | 0.0 | $186k | 220k | 0.84 |
|
Past Filings by NEA Management Company
SEC 13F filings are viewable for NEA Management Company going back to 2010
- NEA Management Company 2024 Q1 filed May 15, 2024
- NEA Management Company 2023 Q4 filed Feb. 14, 2024
- NEA Management Company 2023 Q3 filed Nov. 14, 2023
- NEA Management Company 2023 Q2 filed Aug. 11, 2023
- NEA Management Company 2023 Q1 filed May 15, 2023
- NEA Management Company 2022 Q4 filed Feb. 10, 2023
- NEA Management Company 2022 Q3 filed Nov. 14, 2022
- NEA Management Company 2022 Q2 filed Aug. 15, 2022
- NEA Management Company 2022 Q1 filed May 16, 2022
- NEA Management Company 2021 Q4 filed Feb. 14, 2022
- NEA Management Company 2021 Q3 filed Nov. 12, 2021
- NEA Management Company 2021 Q2 filed Aug. 2, 2021
- NEA Management Company 2021 Q1 filed May 14, 2021
- NEA Management Company 2020 Q4 filed Feb. 16, 2021
- NEA Management Company 2020 Q3 filed Nov. 6, 2020
- NEA Management Company 2020 Q2 filed Aug. 5, 2020